During an ischemic stroke, a blockage in an artery prevents blood flow through the affected area of the brain, resulting in oxygen deprivation and cell death. Ischemic stroke, caused by blood clots, is the most common type of stroke. Dr. Brian MacVicar and Dr. Louis-Philippe Bernier recently uncovered how two types of cells, astrocytes and pericytes, work together to regenerate blood…
Read More
Prostate cancer cells depend on androgens to grow and thrive.  Because of this dependency, hormone therapy – the blockade of androgens and the androgen receptor (AR) – has been the cornerstone of prostate cancer treatment for decades.  As science has progressed, therapies that are better and better at blocking these male hormones and slowing the growth of prostate cancer have…
Read More
UBC and BC Cancer scientists have uncovered some of the tricks used by the deadliest ovarian cancer to escape the immune system, setting the stage for a better understanding of how and why patients respond to promising new immunotherapies. The study, published May 10 in Cell, used advanced molecular measurements and computer algorithms to analyze how immune cells infiltrate tumours. They…
Read More
A scientist who developed a lab test to predict whether children with cancer are susceptible to potentially life-threatening side effects from three chemotherapy drugs is now focusing on five other medications so parents and doctors can discuss safer, personalized treatment. Bruce Carleton, director of the Pharmaceutical Outcomes Programme at BC Children’s Hospital, said adverse reactions linked to the five medications…
Read More

Guarding Women Against One of Their Deadliest Cancers

Research into ovarian cancer could lead to potential life-saving measures. Ovarian cancer is the fifth most common cancer for women—but one of the most deadly. In 2017, approximately 2,800 Canadian women were diagnosed with ovarian cancer1, and an estimated 1,800 lost their lives to the disease. While survival rates are slowly increasing, early diagnosis and treatment dramatically improves a woman’s…
Read More
The largest technology conference in Western Canada is returning is Vancouver — and one of this year’s displays is straight out of a science fiction novel. Beginning Monday and taking place at the Vancouver Convention Centre, the three-day B.C. Tech Summit will showcase new technology that can change industries. Conference speakers include Premier John Horgan and federal Minister of Innovation, Science and Economic Development…
Read More
Cancer treatments can often lead to adverse drug reactions (ADRs) which not only affect the patient’s recovery but can also lead to permanent disabilities and death. For children undergoing cancer treatment, the risk of severe ADRs is even greater. “ADRs in children are three-fold more likely to be life-threatening,” says Martin Ester, a professor in SFU’s School of Computing Science.…
Read More

CDRD Appoints Dr. Lana Janes as Entrepreneur-In-Residence

The Centre for Drug Research and Development, Canada’s national drug development and commercialization centre, is pleased to announce the appointment of Dr. Lana Janes as an Entrepreneur-in-Residence. As a life sciences industry executive for over 20 years, Dr. Janes has extensive pharmaceutical development experience that spans the full life cycle of therapeutic product development from discovery through commercialization. As an…
Read More
The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, and Pfizer Canada today announced the launch of  the CDRD Executive Institute under the umbrella of The CDRD Academy. This launch is made possible by a significant $1,000,000 contribution by Pfizer Canada. The Institute’s aim is to provide ongoing executive development to ensure that the…
Read More
Innovative Targeting Solutions Inc., the global leader in the discovery and optimization of antibodies, today announced a research collaboration with Sanofi. The collaboration uses Innovative Targeting Solutions’ proprietary HuTARG platform to discover novel first-in-class antibody therapeutic candidates. The HuTARG platform, a first-in-class, protein engineering platform, is able to generate large repertoires of fully human antibodies or other protein-based drug modalities, in a mammalian cell…
Read More